MK-4830-002
Phase 2 Completed
160 enrolled 19 charts
KEYVIBE-005
Phase 2 Completed
613 enrolled
IVY
Phase 1 Completed
353 enrolled
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Phase 2 Completed
30 enrolled 7 charts
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
Phase 2 Completed
36 enrolled
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Phase 2 Completed
90 enrolled 10 charts
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Phase 1 Completed
24 enrolled
IP
Phase 1 Completed
30 enrolled
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1 Completed
18 enrolled
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
129 enrolled 17 charts
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Phase 2 Completed
23 enrolled
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
Phase 1 Completed
22 enrolled
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
13 enrolled
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
33 enrolled
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Phase 2 Completed
150 enrolled 11 charts
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 3 Completed
308 enrolled
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
Phase 2 Completed
20 enrolled 8 charts
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
Phase 3 Completed
1,050 enrolled
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Chemotherapy in Treating Patients With Solid Tumors
Phase 1/2 Completed
57 enrolled
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
Phase 1 Completed
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Phase 2 Completed
30 enrolled
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Phase 2 Completed
82 enrolled
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
Phase 2 Completed
48 enrolled 13 charts
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Phase 1 Completed
29 enrolled
TEACO
Phase 2 Completed
132 enrolled 17 charts
OCSTUD
Completed
30 enrolled
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Completed
30 enrolled
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Phase 2 Completed
31 enrolled
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 1/2 Completed
Tax-Over
Phase 2 Completed
37 enrolled
TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
Phase 2 Completed
47 enrolled